California
Biotech Insights

Biotech Market Update

Cellares raises $257M Series D, Eikon files for IPO, Tenpoint wins FDA approval

February 3, 2026

Recent Funding: TRexBio (SF) Raises Additional $50M to Advance Regulatory T Cell Therapies TRexBio extended its Series B by $50 million, bringing total Series B funding to $134 million, to advance its lead drug TRB-061, now in a Phase 1a/b trial for inflammatory diseases, with an initial focus on atopic dermatitis. The new capital gives […]

Biotech Leader Spotlight

Pranav Sharma, Founder and CEO of Xosomix

January 29, 2026

Pranav Sharma is the Founder and CEO of Xosomix, a biotechnology company focused on the use of exosome based platform technology for drug delivery, diagnostics, and therapeutics with a focus on neurological disorders and endometriosis. Previously, during his time at Scripps Research Institute, he made critical scientific contributions towards understanding the role of exosomes in neural circuit development and synaptic plasticity, how neuronal circuit activity regulates integration of new neurons from stem cells inside the brain, discovered a novel pathway of endocytosis, and developed an advanced nanoscale microscopy to elucidate the ultrastructure of lipid rafts in live cells. He obtained Ph.D. in biophysics and cell biology from National Centre for Biological Sciences, Bangalore, India with postdoctoral work at CSHL, Cold Spring Harbor, NY and Scripps Research, San Diego, CA.

Biotech Market Update

Mendra launches with $82M Series A, RAPT acquired by GSK, Janux signs deal with BMS

January 27, 2026

Recent Funding: Mendra (SF) Launches with $82M Series A to Acquire and Commercialize Rare Disease Drugs Mendra raised $82M in a Series A co-led by OrbiMed, 8VC, and 5AM Ventures to identify and acquire underappreciated rare disease medicines that are already post–proof-of-concept or near commercialization. Led by former BioMarin executive Joshua Grass, Mendra plans to […]

Biotech Market Update

Soley raises $200M Series C, Lux Capital raises $1.5B fund, Cartography signs $850M+ deal with Pfizer

January 20, 2026

Recent Funding: Soley Therapeutics (SF) Raises $200M Series C to Advance Stress-Response Drug Platform Soley Therapeutics emerged from stealth with a $200M Series C, bringing total funding to $290M, to advance a drug discovery platform designed to control how cells respond to biological stress – with applications across cancer, obesity, hair loss, and neurodegenerative diseases. […]

Biotech Market Update

Dynavax acquired by Sanofi, Ultragenyx late-stage failure, Crinetics posts strong sales

January 6, 2026

M&A, Deals, Partnerships: Dynavax Technologies (SF) to Be Acquired by Sanofi for $2.2B Cash Sanofi will buy Dynavax for $2.2 billion in cash ($15.50/share) to add Dynavax’s adult hepatitis B vaccine Heplisav-B (a 2-dose series over 1 month vs. the typical 3 doses over 6 months); Heplisav-B generated $90M in Q3 2025 revenue and Dynavax […]

Biotech Market Update

Ambros launches with $125M, Clavis forms $7.25B collaboration with Fosun, BioMarin acquires Amicus

December 23, 2025

Recent Funding: Aeovian Pharmaceuticals (SF) Raises $55M to Advance Selective mTORC1 Therapy for TSC-Related Epilepsy Aeovian secured $55M to complete a Phase 2 trial of AV078, a brain-penetrant, selective mTORC1 inhibitor designed to reduce seizures in tuberous sclerosis complex (TSC), aiming for improved efficacy and fewer side effects than older drugs like rapamycin and everolimus. […]

California Biotech Insights

California
Biotech Insights